Email this article Structum in combined treatmentof low back pain syndrome
- Authors: Mazurov VI1, Belyaeva IB1
-
Affiliations:
- Issue: Vol 79, No 8 (2004)
- Pages: 68-71
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29918
- ID: 29918
Cite item
Full Text
Abstract
Aim. To assess duration of a clinical response and tolerance ofstructum in patients with low back pain
(LBP) and comorbid cardiovascular disease.
Material and methods. 25 patients with primary LBP and coronary heart disease (n = 13) and/or
essential arterial hypertension (n = 18) were examined and treated for 6 months with structum.
Results. To the end of the first treatment months structum significantly relieved pain intensity, spinal
motility, increased exercise tolerance. Excellent and good response to structum were observed in 71%
patients, no response was in 29%. Tolerance of the drug was good in 23 (92%) patients. The effect
persisted for 3 months. СНГ) characteristics did not change while arterial pressure went down noticiably.
Conclusion. Structum is highly effective in the treatment of LBP. Its long-term intake had no effect on
CHD.
(LBP) and comorbid cardiovascular disease.
Material and methods. 25 patients with primary LBP and coronary heart disease (n = 13) and/or
essential arterial hypertension (n = 18) were examined and treated for 6 months with structum.
Results. To the end of the first treatment months structum significantly relieved pain intensity, spinal
motility, increased exercise tolerance. Excellent and good response to structum were observed in 71%
patients, no response was in 29%. Tolerance of the drug was good in 23 (92%) patients. The effect
persisted for 3 months. СНГ) characteristics did not change while arterial pressure went down noticiably.
Conclusion. Structum is highly effective in the treatment of LBP. Its long-term intake had no effect on
CHD.
References
- Шостак Н. А. Современные подходы к терапии боли в нижней части спины. Consilium Medicum 2003; 5 (8): 457-461.
- Шостак Н. А., Аксенова А. В., Правдюк Н. Г. и др. Боли в спине при остеохондрозе позвоночника - перспективы лечения. В кн.: Новые перспективы лечения остеоартроза. М.; 2002. 14-16.
- Gunnar В. J. et al. Epidemiology of low back pain. Acta Or- thop. Scand. 1998; 69 (suppl. 281): 28-31.
- Беленький А. Г., Насонов E. JI. Дорсалгии при воспатительных заболеваниях позвоночника. Рус. мед. журн. 2003; 11 (7): 379-381.
- Беленький А. Г. Дорсалгии при дегенеративных заболеваниях позвоночника. Рус. мед. журн. 2002; 10 (22): 1003- 1005.
- Вознесенская Т. Г. Люмбоишиалгия. Consilium Medicum 2001; 3 (5): 205-208.
- Насонов Е. Д., Насонова В. А. Фармакотерапия боли: взгляд ревматолога. Consilium Medicum 2000; 2 (12): 509- 513.
- Altman R., Luciardi H. L., Muntaner J. et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without 5T-segment elevation. The nonsteroidal anti-inflammatory drugs in unstable angina treatment-2 (NUT-2). Pilot study. Circulation 2002; 106: 191.
- Konstam M. A., Weir M. R., Reicin A. et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104 (19): 2280-2288.
- Knijff-Dutmer E. A. J., Kalsbeek-Batenburg E. M., Koerts J. et al. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology 2002; 41: 458-461.
- Layton D., Heeley E., Hughes K. et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (РЕМ) data. Rheumatology. Advance Access published. 2003; keg379.
- Happey F., Wiseman A., Naylor A. Biochemical aspects of intervertebral discs in aging and disease. In: Jayson M., ed. Lumbar spine and back pain. New York: Grune Strantton: 1976.318.
- Насонов E. JI., Алексеева JI. И. Хондроитин сульфат (структум) при лечении остеоартроза: патогенетическое обоснование и клиническая эффективность. В кн.: Новые перспективы лечения остеоартроза. М.: 2002. 2-4.
- Алексеева Л. И., Архангельская Г. С. и др. Отдаленные результаты применения структума (по материалам многоцентрового исследования). Тер. арх. 2003; 9: 82-86.
- Baker С. S. R., Hall R. J. С, Evans Т. J. et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with iducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler. Thromb. Vase. Biol. 1999; 19: 646-655.
- Якушева В. А. Клинические особенности течения ишемической болезни сердца у больных ревматоидным артритом: Дис. ... канд. мед. наук. СПб; 2003.
- Belton О., Byrne D., Kearney D. et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
- Насонов Е. Л. Иммунологические маркеры атеросклероза. Тер. арх. 2002; 5: 80-85.
Supplementary files
